4:05 PM ET
8-K
Shareholder Meeting
Cadrenal Therapeutics Shareholder Meeting
Cadrenal Therapeutics held its 2026 Annual Meeting of Stockholders where shareholders elected Quang X. Pham as a Class I director and ratified WithumSmith+Brown, P.C. as the independent auditor. Stockholders also approved an amendment to the 2022 Successor Equity Incentive Plan to increase the share pool by 323,542 shares and authorized the issuance of up to 960,000 shares upon the exercise of certain warrants.